BetterLife Pharma Inc.
BETRF · OTC
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -0.07 | 0.18 | 0.02 |
| FCF Yield | -0.12% | -1.12% | -0.12% | -0.12% |
| EV / EBITDA | -26.62 | 0.00 | -97.74 | -20.61 |
| Quality | ||||
| ROIC | 7.07% | 10.29% | 6.50% | 12.54% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.03 | 0.35 | 0.07 | 0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 95.09% | -1,109.62% | 25.76% | 86.49% |
| Safety | ||||
| Net Debt / EBITDA | -1.70 | 0.00 | -9.89 | -1.58 |
| Interest Coverage | -10.88 | -15.19 | -4.03 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |